Royalty Pharma plc RPRX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 671.45M | 810.99M | 825.29M | 769.95M | 763.96M |
| Total Depreciation and Amortization | 4.88M | 4.94M | 5.02M | 3.85M | 2.66M |
| Total Amortization of Deferred Charges | 31.21M | 30.79M | 31.03M | 28.64M | 26.40M |
| Total Other Non-Cash Items | -1.27B | -1.40B | -1.66B | -1.65B | -1.59B |
| Change in Net Operating Assets | 3.52B | 3.53B | 3.41B | 3.34B | 3.20B |
| Cash from Operations | 2.96B | 2.98B | 2.61B | 2.49B | 2.41B |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -226.00K | -74.42M | -74.42M | -74.42M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.84B | -2.51B | -2.52B | -1.54B | -1.20B |
| Cash from Investing | -1.84B | -2.51B | -2.60B | -1.61B | -1.27B |
| Total Debt Issued | 50.00M | 3.23B | 3.23B | 3.23B | 3.23B |
| Total Debt Repaid | -430.00M | -2.28B | -2.28B | -2.28B | -2.28B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -261.62M | -321.77M | -568.70M | -1.23B | -1.20B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -408.87M | -399.06M | -387.39M | -378.25M | -377.57M |
| Other Financing Activities | -493.67M | -516.32M | -515.73M | -534.81M | -521.80M |
| Cash from Financing | -1.54B | -282.68M | -517.34M | -1.19B | -1.14B |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -425.29M | 180.08M | -501.33M | -310.33M | -11.11M |